Table 2.
Treatment history
| Variable | Overall (N = 154) | Asymptomatic (n = 17) | Mildly symptomatic (n = 48) | Moderately symptomatic (n = 50) | Severely symptomatic (n = 39) |
|---|---|---|---|---|---|
| Currently (past 30 days) receiving MM therapy (n (%)) | 80 (52) | 7 (41) | 19 (40) | 33 (66) | 21 (54) |
| Type of current MM therapy (n (%)) | |||||
| Bortezomib containing | 37 (46) | 3 (43) | 7 (37) | 19 (58) | 8 (38) |
| Lenalidomide containing | 17 (21) | 3 (43) | 4 (21) | 6 (18) | 4 (19) |
| Thalidomide containing | 15 (19) | 1 (14) | 6 (32) | 4 (12) | 4 (19) |
| Alkylating agents containing | 8 (10) | 0 | 2 (11) | 4 (12) | 2 (10) |
| Other | 3 (4) | 0 | 0 | 0 | 3 (14) |
| Number of prior MM therapies in the past 12 months (n (%)) | |||||
| 0 | 88 (57) | 11 (65) | 29 (60) | 28 (56) | 20 (51) |
| 1 | 49 (32) | 3 (18) | 15 (31) | 18 (36) | 13 (33) |
| 2 | 13 (8) | 3 (18) | 3 (6) | 3 (6) | 4 (10) |
| ≥3 | 4 (3) | 0 | 1 (2) | 1 (2) | 2 (5) |
| Type of prior MM therapy in the past 12 months (n (%)) | |||||
| Bortezomib containing | 28 (18) | 5 (29) | 4 (8) | 9 (18) | 10 (26) |
| Lenalidomide containing | 3 (2) | 0 | 1 (2) | 2 (4) | 0 |
| Thalidomide containing | 31 (20) | 2 (12) | 12 (25) | 9 (18) | 8 (21) |
| Alkylating agents containing | 17 (11) | 2 (12) | 5 (10) | 5 (10) | 5 (13) |
| Other | 6 (4) | 0 | 2 (4) | 1 (2) | 3 (8) |
MM multiple myeloma